*By Conor White* Lemonade, the insurance startup that uses A.I. and chatbots to pay claims within seconds, saw exponential growth in the U.S. in 2018, but the company is setting its sights on Europe for its next phase of expansion. "We've decided that if people in Berlin, and Tokyo, and New York are using Spotify ($SPOT), and Netflix ($NFLX), and Uber, why not Lemonade?" CEO and co-founder Daniel Schreiber asked in an interview on Cheddar. The burgeoning company's tech-driven approach has caught the attention of some of its more traditional competitors. That includes State Farm, which [released an ad in October](https://youtu.be/KIWfc9aI1YI) poking fun at artificial intelligence and robots, a not-so-thinly veiled dig at the startup. But Schreiber said he didn't mind the mockery. "We found it remarkable that ... the largest insurance company in the nation, that \[is\] a thousand times bigger than Lemonade, would spend millions of dollars taking us on," Schreiber said. "I really found that interesting and deeply flattering honestly." The company even took the unusual step of paying to promote the ad online. "They're mocking us," Schreiber explained, "but I really think it's a bit of a boomerang that comes back and hurts them much more than it hurts us." The CEO highlighted some of Lemonade's 2018 accomplishments, including $57 million in sales and increasing the number of homes it insures by more than 300,000. But Schreiber said he is proudest of his company's reputation with customers. "You go now to any of the consumer ratings sites, and you'll find that USAA and Lemonade compete for the number one spot in terms of customer satisfaction," he said. "Growing fast is fabulous," he said, "but if you do it at the expense of customer satisfaction, that's a price not worth paying." For full interview [click here](https://cheddar.com/videos/lemonade-insurance-plans-european-expansion).

Share:
More In Business
Regeneron Joins Battle Against COVID-19, Releases Stats on New COVID Treatment
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Peloton Stock Continues Steep Drop as It Loses More Than $10B in Value
Doug Astrop, managing partner at Exponential Investment Partners, joined Cheddar to discuss Peloton's precipitous price drop, and whether the company can recover as the at-home workout trend tapers off. "They've lowered the prices on their equipment to try to attract a bigger audience because ultimately they're sort of headed to this Apple ecosystem model where they can monetize a loyal customer base," he said. Astrop noted that he believes there is a reality where the in-person gym experience and Peloton's at-home programs can co-exist.
Markets Look to Continue Record Run
Bill Stone, Chief Investment Officer at Glenview Trust Company, joined Wake Up With Cheddar to break down markets headlines ahead of the start of the trading week.
Load More